Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients - Wikidata - awgldk - TriplyDB

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

http://www.wikidata.org/entity/Q24633820

about

Trial Watch Ways to enhance lymphocyte trafficking into tumors and fitness of tumor infiltrating lymphocytes Characterization of Potent SMAC Mimetics that Sensitize Cancer Cells to TNF Family-Induced Apoptosis Immunotherapy for ovarian cancer.Peptide-mediated targeting of cytokines to tumor vasculature: the NGR-hTNF example.Beyond bevacizumab: investigating new angiogenesis inhibitors in ovarian cancer.From amino acid sequence to bioactivity: The biomedical potential of antitumor peptides.Systemic and tumor-targeted delivery of siRNA by cyclic NGR and isoDGR motif-containing peptides.The tumor vessel targeting agent NGR-TNF controls the different stages of the tumorigenic process in transgenic mice by distinct mechanisms.Succinimide Formation from an NGR-Containing Cyclic Peptide: Computational Evidence for Catalytic Roles of Phosphate Buffer and the Arginine Side Chain Advances in systemic therapy for malignant mesothelioma: future perspectives.Phosphate-Catalyzed Succinimide Formation from an NGR-Containing Cyclic Peptide: A Novel Mechanism for Deammoniation of the Tetrahedral Intermediate

P2860

Q24618653-E9CD1F10-194F-47BB-9A1C-DF18268CEA64 Q26991991-CC9DB0F9-9EF2-4E0A-BD10-E9C25CB28D89 Q34540067-7B3226BB-5877-4333-A7F1-1C4BBB03D43F Q35164189-B1644235-63E1-45A5-9388-D28157B293C3 Q38112578-8CBA6F45-651A-45E9-B14C-005C9836B0B8 Q38151193-7B803E14-AA4E-42DB-9B9B-F83657ABB17F Q38787128-4C4515C7-6792-4A64-8776-EA8BF3CAFBAE Q38801839-F58CF162-9764-4A30-A9EC-59E32100C45E Q41577994-52F31D15-04E4-4D6E-846E-57BE39C1DB95 Q41981559-0ABDFA8C-8C5B-4F3A-858B-7D58C58B81BF Q47912434-9D3BD9D0-3223-404D-82CB-DFF7EFA1F3F8 Q58696582-EF86E253-A9C4-4C66-8EA1-F067E672D229

P2860

Phase II study of NGR-hTNF in combination with doxorubicin in relapsed ovarian cancer patients

http://www.wikidata.org/entity/Q24633820

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@ast

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@en

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@nl

type

label

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@ast

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@en

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@nl

prefLabel

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@ast

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@en

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@nl

P1433

Q24633820-F0101333-E2BF-4003-90DE-14F45930E073

P1476

Q24633820-D2284002-4B27-4DCD-9DAA-3C2C705F39F2

P2093

Q24633820-0FE00AC1-C725-4D10-8EA3-47D6D216D4B2

Q24633820-19632BAD-5DC9-4CB5-99E2-FC66D064C0A7

Q24633820-6A53F77E-CAC1-4529-84F1-DD3E7518D93A

Q24633820-7AEA21A9-1C12-4472-9AE9-66DB0D6A2E0B

Q24633820-7AF096A6-EA72-4984-8C68-263EA6BD4A92

Q24633820-7FC0635C-80AE-4881-959F-D6BBA646108A

Q24633820-9490C97E-A859-4CAF-96F6-4A8F8FC86599

Q24633820-D35F8D2C-5CC2-4753-B91C-0D8375C82BE8

Q24633820-DB0C99E4-A68F-4A22-B9C6-687C7357F22F

P2860

Q24633820-06E0BB47-E77C-4AC8-8539-E481BEEE3940

Q24633820-097894B4-1745-438D-804C-7E5D6F672FD8

Q24633820-0A73F0E3-A883-43C2-99E9-2D0C4E922606

Q24633820-1CC8AFFA-B07E-479B-AA73-054336CF0A14

Q24633820-25AA680C-59B2-4C09-8851-F7A42F6CD954

Q24633820-289F1F14-48E1-42AE-9315-163468A7FDE5

Q24633820-356974C7-3CCB-408E-AB3F-2FBBB0B90CE6

Q24633820-35DDA6B2-12C1-4749-B6F9-0D2B2BABBE8C

Q24633820-36C689FF-CA3E-458C-B76A-CDDF0EF32B4F

Q24633820-3BCE9050-144E-45F7-B7B0-BE1FACC7499D

P2888

Q24633820-74380524-CB20-401B-9289-26213A55F53B

P304

Q24633820-E280923E-8E9B-4383-B2D5-A97DAD8158E6

P31

Q24633820-DECE1E77-BB71-4BDB-B889-63CFAAE61D7A

P3181

Q24633820-6B989788-1E00-4A38-99A4-F053ABF46D13

P356

Q24633820-014B576A-82AF-4277-A0EF-408C9C4C77F4

P407

Q24633820-59E2F073-3FD0-4BC4-B5FB-F4834AF5C7B9

P433

Q24633820-2807F170-3475-4560-91B1-77FB725440D7

P478

Q24633820-0185FAFD-CF1F-45FE-99AA-5BEE5E8C7389

P50

Q24633820-145B60D0-27B4-4F00-B987-0BF1B002774A

Q24633820-CE1546C5-A1A5-49B4-8BCC-752703FE23E1

Q24633820-D73BA842-DD2C-40E1-B8A7-D7A79770157D

Q24633820-FEE90D1C-83EC-4386-A706-31EFA2CF65C1

P577

Q24633820-FD361B87-07F1-49F1-9477-DCD23D2F3538

P5875

Q24633820-76DCAB69-1748-4F15-8151-94885283C744

P6179

Q24633820-F3C9FA87-E149-42C5-8BFB-683A22105F98

P698

Q24633820-6AB7F0E6-982D-4BCB-A339-0EB503D488D3

P921

Q24633820-84D3D376-8258-499A-BDB5-F074E16E75DA

P932

Q24633820-A26ACF6C-43A6-404E-8CF7-DD14CFC08135

P3181

P356

P1433

British Journal of Cancer

P1476

Phase II study of NGR-hTNF in ...... lapsed ovarian cancer patients

@en

P2093

A Lambiase

http://www.w3.org/2001/XMLSchema#string

A di Legge

http://www.w3.org/2001/XMLSchema#string

C Bordignon

http://www.w3.org/2001/XMLSchema#string

G Amadio

http://www.w3.org/2001/XMLSchema#string

G Citterio

http://www.w3.org/2001/XMLSchema#string

G Scambia

http://www.w3.org/2001/XMLSchema#string

M Di Stefano

http://www.w3.org/2001/XMLSchema#string

M Mantori

http://www.w3.org/2001/XMLSchema#string

V Masciullo

http://www.w3.org/2001/XMLSchema#string

P2860

Global cancer statistics

An endotoxin-induced serum factor that causes necrosis of tumors

Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer

Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Low-dose tumor necrosis factor-alpha augments antitumor activity of stealth liposomal doxorubicin (DOXIL) in soft tissue sarcoma-bearing rats.

Activity and safety of NGR-hTNF, a selective vascular-targeting agent, in previously treated patients with advanced hepatocellular carcinoma.

Cancer of the ovary.

Trabectedin plus pegylated liposomal doxorubicin in relapsed ovarian cancer: outcomes in the partially platinum-sensitive (platinum-free interval 6-12 months) subpopulation of OVA-301 phase III randomized trial

Use of CA-125 to assess response to new agents in ovarian cancer trials.

Impaired angiogenesis in aminopeptidase N-null mice.

P2888

P304

37-42

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

3575561

http://www.w3.org/2001/XMLSchema#string

P356

10.1038/BJC.2012.233

http://www.w3.org/2001/XMLSchema#string

P407

P433

1

http://www.w3.org/2001/XMLSchema#string

P478

107

http://www.w3.org/2001/XMLSchema#string

P50

Domenica Lorusso

Rosa De Vincenzo

P577

2012-05-29T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

225073497

http://www.w3.org/2001/XMLSchema#string

P6179

1047029393

http://www.w3.org/2001/XMLSchema#string

P698

22644293

http://www.w3.org/2001/XMLSchema#string

P921

P932

3389423

http://www.w3.org/2001/XMLSchema#string